Daily Market Research Report

October 22, 2025

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - IPO Calendar: Upcoming initial public offerings and market debuts - Stock Ratings: Latest analyst ratings and target prices for our watchlist

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA

This report is generated using advanced AI research capabilities with real-time market data access.

IPO Calendar

Timeframe: October 22, 2025 to November 22, 2025 (US equity markets)

Activity remains resilient despite the ongoing US government shutdown slowing some SEC processing. Issuers with up-to-date filings are using the automatic effectiveness path (Section 8(a)/Rule 473) to keep roadshows on track. The coming month skews toward healthcare/biotech (MapLight Therapeutics; BillionToOne), tech-enabled services (Navan), and electric aviation (Beta Technologies), with a notable cross-border airline listing (Aeroméxico). Micro-cap listings (e.g., DT House, Texxon) continue on Nasdaq’s Capital Market with smaller raises and single-bookrunner structures. Expect timing to be fluid; several deals are “expected” rather than firm due to market and regulatory conditions. citeturn0news14turn4search3turn7search4turn18news12turn3news12

MapLight Therapeutics, Inc. (MPLT)

• Expected listing date: 2025-10-28
• Price range: Priced at $17.00 per share (14.75M shares); 15% over-allotment option (2.2125M).
• Shares offered: Primary: 14,750,000; Over-allotment: up to 2,212,500; Concurrent private placement: 476,707 shares to Goldman Sachs affiliates.
• Exchange: Nasdaq Global Market
• Lead underwriters: Morgan Stanley, Jefferies, Leerink Partners, Stifel
• Business summary: Clinical-stage biotech developing circuit-specific pharmacotherapies for CNS disorders (lead programs include ML-007C-MA and ML-004). The deal uses a fixed per‑share price structure consistent with automatic effectiveness mechanics during the shutdown. citeturn7news12turn7search1turn7search4
• Notes: Company announced offering terms and Nasdaq application; pricing at a fixed $17 reflects reliance on automatic effectiveness. Listing and settlement subject to customary conditions. citeturn7search1turn7search4
• Sources: PR Newswire: MapLight announces IPO terms (Oct 6, 2025), SEC: Form S-1/A (filed Oct 6, 2025), Reuters coverage (Oct 6, 2025)

Navan, Inc. (NAVN)

• Price range: $24.00–$26.00 per share.
• Shares offered: Total offered: 36,924,406 (30,000,000 primary; 6,924,406 secondary); greenshoe up to 5,538,660.
• Exchange: Nasdaq Global Select Market
• Lead underwriters: Goldman Sachs, Citigroup, Jefferies, Mizuho, Morgan Stanley
• Business summary: Corporate travel, payments, and expense management platform (formerly TripActions) targeting up to ~$960M gross proceeds at the top of the range, implying up to a ~$6.45B valuation. citeturn0news12turn4search3
• Notes: Roadshow launched Oct 21, 2025; pricing/first trade timing will depend on market conditions and SEC processing. Several additional bookrunners named (BNP Paribas, Citizens, Oppenheimer, MUFG, Needham, BTIG). Estimated debut has circulated for late October, but the company has not published a listing date. citeturn4search3turn4search5turn4search7
• Sources: Company press release: IPO roadshow launch (Oct 21, 2025), Reuters overview of range/valuation (Oct 10, 2025), StockAnalysis listing snapshot (as reference)

BETA Technologies, Inc. (BETA)

• Expected listing date: 2025-11-03 (expected)
• Price range: $27.00–$33.00 per share.
• Shares offered: Primary: 25,000,000; greenshoe up to 3,750,000; indicated interest ~$300M from cornerstone investors.
• Exchange: New York Stock Exchange
• Lead underwriters: Morgan Stanley, Goldman Sachs, BofA Securities, Jefferies, Citigroup
• Business summary: Electric aircraft developer (eCTOL/eVTOL platform), with propulsion and charging systems; targeting up to $825M raise and ~$7.2B valuation at the midpoint, supported by cornerstone indications. citeturn18news12
• Notes: Expected NYSE listing date Nov 3, 2025 per deal calendars; final timing subject to market/SEC mechanics during the shutdown. Additional bookrunners include Cantor, BTIG, Needham. citeturn18search6turn18search1
• Sources: Reuters: sets terms and valuation (Oct 15, 2025), IPOX calendar (expected Nov 3, 2025), Investing.com launch note (Oct 15, 2025)

Grupo Aeroméxico, S.A.B. de C.V. (ADS) (AERO)

• Price range: $18.00–$20.00 per ADS (each ADS = 10 ordinary shares).
• Shares offered: US tranche: 11,727,325 ADS (7,394,409 primary; 4,332,916 secondary); 30‑day option up to 2,171,050 ADS. Concurrent Mexican offering and $25M private placement to PAR at 95% of IPO price.
• Exchange: New York Stock Exchange (ADS)
• Lead underwriters: Barclays, Morgan Stanley, J.P. Morgan, Evercore ISI
• Business summary: Mexico’s full-service flag carrier returning to public markets after its 2022 Chapter 11 emergence; proceeds support balance sheet and broader dual‑listing strategy (US ADS and BMV common). citeturn9search0turn3news12
• Notes: Terms set Oct 17, 2025; pricing/first trade date not yet announced at time of writing. Dual offering structure and ongoing shutdown conditions may influence final timing. citeturn9search0
• Sources: Company release: amended registration/terms (Oct 17, 2025), Reuters terms/valuation (Oct 17, 2025), Renaissance Capital note (Oct 17, 2025)

BillionToOne, Inc. (BLLN)

• Price range: $49.00–$55.00 per share (range disclosed).
• Shares offered: 3,800,000 shares (all Class A); proceeds up to ~$211.5M at the top of the range (before options).
• Exchange: Nasdaq (proposed)
• Lead underwriters: J.P. Morgan, Wells Fargo, William Blair
• Business summary: Molecular diagnostics company focused on NIPT and oncology liquid biopsy tests; strong recent revenue growth with improving losses; targeting >$2B valuation. citeturn3news13
• Notes: Filed and set a price range; listing date not yet announced. Timing likely late Oct/early Nov subject to market/SEC conditions. citeturn8search3
• Sources: Reuters filings/terms (Oct 7 & Oct 17, 2025)

Park Dental Partners, Inc. (PARK)

• Expected listing date: 2025-10-24 (expected)
• Price range: $12.00–$14.00 per share.
• Shares offered: ~1,535,000 shares (per S-1/A terms) with standard 15% over‑allotment option typical for small-cap IPOs.
• Exchange: Nasdaq Capital Market
• Lead underwriters: Northland Capital Markets, Craig-Hallum Capital Group
• Business summary: Dental resource organization providing business support and clinical staffing to affiliated general and multi‑specialty dental practices across MN/WI; ~$234M LTM revenue through Jun 30, 2025. citeturn17search6turn17search0
• Notes: Company has filed and set terms; third‑party calendars place the debut around Oct 24, 2025. Small‑cap healthcare‑services IPOs commonly shift by a few days based on demand and exchange clearance. citeturn2search7
• Sources: Company press release: S‑1 filing/underwriters (Sept 3, 2025), Renaissance Capital: terms set (Sept 24, 2025), StockAnalysis date reference

Texxon Holding Limited (NPT)

• Expected listing date: 2025-10-23 (expected)
• Price range: $4.00–$5.00 per share.
• Shares offered: 2,000,000 shares; over‑allotment up to 300,000 (15%).
• Exchange: Nasdaq Capital Market
• Lead underwriters: D. Boral Capital LLC
• Business summary: China‑based plastics and chemicals supply‑chain platform serving SME customers with procurement, logistics, payments and fulfillment; intends to fund a Henan polystyrene facility and platform upgrades. citeturn16view0
• Notes: SEC shows effectiveness and exchange registration; the company’s FWP lists D. Boral Capital as underwriter. Trading date guidance varies by calendar vendors (Oct 22–23). citeturn12view0
• Sources: SEC: Free Writing Prospectus naming underwriter (Aug 27, 2025), SEC: Notice of Effectiveness and 8‑A12B (Sept 30, 2025), StockAnalysis date reference

DT House Limited (DTDT)

• Expected listing date: 2025-10-24 (expected)
• Price range: $4.00–$5.00 per share.
• Shares offered: 2,000,000 shares; standard 15% over‑allotment option indicated in filings.
• Exchange: Nasdaq Capital Market
• Lead underwriters: American Trust Investment Services, Inc.
• Business summary: UAE‑headquartered corporate ESG consultancy with supplemental UAE leisure travel services; small‑cap Cayman holding company with operating subsidiaries in the UAE and Hong Kong. citeturn10search2
• Notes: Underwriter changed from Revere Securities to American Trust Investment Services in June 2025 F‑1/A. Timing remains subject to demand and exchange clearance; third‑party calendars list Oct 24, 2025. citeturn10search2turn6search2
• Sources: SEC: F‑1/A (June 18, 2025) – Underwriting section, StockAnalysis date reference

Dates and deal sizes can change or slip, especially during the government shutdown. Some entries list “expected” dates from reputable calendars; where issuers or exchanges have not confirmed, fields are marked accordingly. Micro‑cap offerings may change bookrunners or timing close to pricing; rely on the latest prospectus/424B filings at pricing.

Stock Ratings

Error retrieving stock ratings information: Connection error.

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2025-10-22 at 11:22 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.

Powered by Alpha Signal Monitor | Market Intelligence Through AI